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METHODS: Patients received twice-daily doses of tapentadol ER (100–250 mg), 
oxycodone HCl controlled release (CR; 20–50 mg), or placebo over a 15-week treat-
ment period. Patients completed the EQ-5D (evaluates mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression) at baseline and at prespeciﬁed time 
points. RESULTS: Efﬁcacy and safety were evaluated for 1,023 patients who received 
q1 dose of study medication. Overall, the change from baseline in the EQ-5D health 
status index was signiﬁcantly greater with tapentadol ER versus both oxycodone CR 
and placebo (least squares mean difference [95% conﬁdence interval] between tapen-
tadol ER and oxycodone CR, 0.07 [0.03,0.10; P  0.001]; between tapentadol ER 
and placebo, 0.05 [0.02,0.09; P  0.004]). Differences between oxycodone CR and 
placebo were not signiﬁcant (−0.01 [−0.05,0.02; P  0.449]). Across all treatment 
groups at baseline, the percentages of patients reporting no problems in each of 
the EQ-5D dimensions were as follows: mobility, 9%–10%; self-care, 77%–82%; 
usual activities, 14%–17%; pain/discomfort, 0%–1%; and anxiety/depression, 
68%–70%. At endpoint, the percentages of patients reporting no problems 
were mobility: placebo, 16.3%; tapentadol ER, 25.0%; oxycodone CR, 16.7%; 
self-care: placebo, 75.1%; tapentadol ER, 81.1%; oxycodone CR, 80.1%; usual 
activities: placebo, 26.1%; tapentadol ER, 33.7%; oxycodone CR, 27.2%; pain/
discomfort: placebo, 5.6%; tapentadol ER, 9.0%; oxycodone CR 4.7%; and anxiety/
depression: placebo, 71.8%; tapentadol ER, 70.9%; oxycodone CR, 69.6%. A total 
of 61.1%, 75.9%, and 87.4% of patients who received placebo, tapentadol ER, and 
oxycodone CR, respectively, reported q1 treatment-emergent adverse event. CON-
CLUSIONS: Treatment with tapentadol ER (100–250 mg bid) signiﬁcantly improved 
overall health status compared with placebo and oxycodone HCl CR (20–50 mg bid) 
in patients with moderate to severe chronic osteoarthritis knee pain.
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OBJECTIVES: The aim of the current study was to compare the efﬁcacy of pharma-
cological treatments for the management of ﬁbromyalgia with particular focus on 
outcomes considered most important by the Outcome Measures in Rheumatoid 
Arthritis Clinical Trials (OMERACT) symposium. METHODS: A systematic review 
was conducted to identify randomised controlled trials (RCTs) evaluating pharmaco-
logical treatments in adults with ﬁbromyalgia. A Bayesian MTC was performed in 
WinBUGS to estimate the relative efﬁcacy of the evaluated treatments. The primary 
efﬁcacy outcome was the absolute reduction in pain score at study endpoint, based 
on visual analogue or numerical rating scales. Secondary efﬁcacy outcomes included 
proportion of patients responding, changes in Fibromyalgia Impact Questionnaire 
(FIQ) total score, sleep and quality of life measures. Random-effects models were used 
to account for any heterogeneity; ﬁxed-effects models were evaluated in sensitivity 
analysis. RESULTS: Eleven RCTs were included in the review, with 21 RCTs meeting 
criteria for inclusion in the meta-analysis (ﬁxed-dosing regimen, parallel-group study 
design, and high quality [Jadad score q3]). Ten RCTs reported data on the primary 
outcome measure suitable for inclusion in the MTC. These trials evaluated nine treat-
ment regimens: alprazolam, citalopram, duloxetine, ibuprofen, milnacipran, parox-
etine, placebo, pregabalin, ibuprofen  alprazolam. Results from a random-effects 
MTC found that only pregabalin 300, 450, 600 mg/day and duloxetine 20, 60, 
120 mg/day produced signiﬁcantly greater reductions in pain score (p  0.05) than 
placebo. Duloxetine 120 mg/day was signiﬁcantly superior to citalopram 20 mg/day 
and milnacipran 100 mg/day (p  0.05), with no other statistically signiﬁcant differ-
ences reported between active treatments. CONCLUSIONS: Only 21 studies met the 
inclusion criteria for the MTC reﬂecting the relatively poor quality of the majority of 
published studies. Of the treatments included in the MTC of the primary outcome, 
only pregabalin and duloxetine were signiﬁcantly superior to placebo for pain relief.
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OBJECTIVES: Cost-effectiveness models of biologic treatments for RA have been 
shown to be strongly affected by improved physical function, as measured by HAQ-
DI. This analysis was conducted to focus on patients receiving continuous treatment 
with tocilizumab (TCZ) 8 mg/kg monthly and conventional anti-rheumatic medica-
tions for more than 24 weeks, while assessing HAQ-DI scores. METHODS: HAQ-DI 
scores in patients with moderate to severe RA were obtained from the 8-mg/kg treat-
ment groups of three extension studies of four randomised, placebo-controlled studies. 
Analysis focused on observations at or after week 24 to assess the long-term effects 
of treatment. Week 192 was chosen as a cut-off to preserve sufﬁcient sample size. 
Analysis of mean HAQ-DI scores (average at each time window) was conducted for 
all observations. Parallel analysis was conducted separately for patients who received 
previous therapy with anti-TNF agents that did or did not fail. A trendline was ﬁtted 
to the data to describe the overall trend and assess its linearity. In addition, a mixed 
linear model of HAQ-DI as a function of time was estimated at the patient level. 
RESULTS: A total of 1422 patients were available at week 24. Nearly 40% (546) 
have been observed through week 156, and 56 have been observed through week 192. 
All-observed analysis showed a strong linear relationship with a slow, steady decrease 
in HAQ-DI scores through week 192 (week 24  1.05; week 192  0.88; slope  
0.015; R2  0.87). HAQ-DI improvement was monotonic through week 156. Strati-
ﬁcation by previous failure of anti-TNF therapy produced similar ﬁndings. Patient-
level mixed-model results were consistent, showing a signiﬁcant downward slope. 
CONCLUSIONS: Patients with RA treated with 8 mg TCZ in combination with 
standard anti-rheumatic medications have steadily improving HAQ-DI scores while 
on treatment through week 192. Cost-effectiveness models of TCZ should include 
these ﬁndings to accurately gauge the utility of treatment.
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OBJECTIVES: To compare dosing patterns between duloxetine and pregabalin among 
patients with ﬁbromyalgia. METHODS: Using a large US administrative claims data-
base, we examined commercially insured individuals aged 18–64 with ﬁbromyalgia 
who initiated duloxetine or pregabalin in 2006. Initiation was deﬁned as 90-day 
medication gap, with the dispense date of the ﬁrst initiation as the index date. All 
patients included had 12-month continuous enrollment in the pre- and post-index 
period, and at least 30 days supply of duloxetine or pregabalin in the 12 months 
post-index period. Patients with diabetic peripheral neuropathic pain or depression in 
the 12 months pre-index period were excluded. Duloxetine or pregabalin cohorts were 
constructed based on the index agent. Average daily doses of all duloxetine or prega-
balin prescriptions per person, average daily dose in each of the ﬁrst 12 prescriptions, 
and percent of daily dose change from previous prescription were compared between 
duloxetine and pregabalin cohorts. RESULTS: Both the duloxetine (n  3773) and 
pregabalin (n  4189) cohorts had the mean age of 50 years. The duloxetine cohort 
had an average initial daily dose of 55.7 mg, while 161.5 mg for the pregabalin cohort. 
The average daily dose per patient was 55.5 mg for duloxetine and 195.7 mg for pre-
gabalin. The average daily doses for the ﬁrst through twelfth duloxetine scripts varied 
from 55.68 mg (95% Conﬁdence Interval (CI): 54.96, 56.40) to 60.34 mg (95% CI: 
54.71, 65.97), while the numbers were 161.50 mg (95% CI: 159.02, 163.98) and 
282.41 mg (95% CI: 266.89, 297.93) for pregabalin. The percentages of changes in 
daily dose from previous prescriptions were 4.2^1.6% for duloxetine and 1.3^14.3% 
for pregabalin, respectively. CONCLUSIONS: Among patients with ﬁbromyalgia, 
duloxetine and pregabalin initiators had very different dosing patterns. The average 
daily dose for duloxetine was relatively stable over time, while pregabalin patients had 
signiﬁcant dose escalation over the 12-month follow-up period.
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OBJECTIVES: To assess the estimated prevalence of ﬁbromyalgia sufferers in Russia          
among the general adult population. METHODS: To The validated Russian version     
of the screening questionnaire was administrated to a representative community 
sample (n  1610), deﬁned by IPSOS® according to the quotas method (sex, age, 
householder’s profession) with a stratiﬁcation according to the region / cities commu-
nity. The LFESSQ questionnaire allows to screen patients who might have ﬁbromyal-
gia. The LFESSQ questionnaire allows to screen patients who might have ﬁbromyalgia.            
A positive screen was deﬁned as: meeting the 4-pain criteria alone (LFESSQ-4), or 
meeting both the 4-pain and 2-fatigue criteria (LFESSQ-6). The questionnaire was 
submitted to a sample of rheumatology outpatients (n  399), who were then examined 
by a trained rheumatologist to conﬁrm or exclude the diagnosis of FM according to 
the 1990 American College of Rheumatology criteria. The prevalence of FM in the 
general population was estimated by applying the predictive positive value to eligible 
community subjects (i.e., positive screens). RESULTS: The community sample is con-    
stituted of 885 females and 725 men. 20.1% screened positive for LFESSQ-4 (25.3% 
in females and 13.7% in males respectively). A total of 13.8% screened positive for 
LFESSQ-6 (18.4% in females and 8.1% in males, respectively). Among rheumatology 
outpatients, 43.6% were screened positive for LFESSQ-6 (44.3% in females and 
40.5% in males, respectively), whereas 6.5% were conﬁrmed FM cases (ACR criteria). 
The prevalence of FM was estimated at 2.1% (95% CI: 1.4%–2.8%, 2.8% in females 
and 1.2% in males respectively) in the Russian general population. CONCLUSIONS: 
Our ﬁndings are in agreement with those of earlier national survey reports and previ-
ous publications in US, Canada and Spain. A point prevalence of 2.1 % would trans-
late in approximately 2.5 million of patients with FM in Russia.
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OBJECTIVES: Secular decreases in hip fracture rates have been reported in some 
countries. Whether this phenomenon applies to other fracture sites has not been 
studied. Our objective was to examine fracture patterns across twenty years in a 
